Dr. Shirin Abbasinejad Enger is a tenured Associate Professor at the Medical Physics Unit, Gerald Bronfman Department of Oncology, interim Co-Director at the Medical Physics Unit and holder of a Tier 2 Canada Research Chair in Medical Physics. She is research director in Translational Physics and Radiobiology at the Lady Davis Institute and Segal Cancer Centre of the Jewish General Hospital. 
Dr. Abbasinejad Enger received her Ph.D. degree from Uppsala University in 2009 and was a postdoctoral fellow at Université Laval from 2009 to 2011. She has several leadership roles in international and national workgroups and committees. She is chair of the Intensity Modulated and Anisotropic Brachytherapy Sources Task Group (TG-337) and member of multiple other work and task groups at the American Association of Physicists in Medicine. This includes the workgroup on Science Council Equity, Diversity and Inclusion. She is member of the Science  Committee and Women’s Committee at the Canadian Association of Medical Physicists. 

Dr. Abbasinejad Enger’s multidisciplinary research involves development of applied technology to address current limitations in radiotherapy treatment and imaging of cancer. She has multiple patents and has received competitive funding to develop her innovations from proof of concept to clinical trials. Her research group has won several medical innovation awards and several papers published by her group have been selected as editor’s pick in major peer-reviewed journals in the field.
Her research on rectal cancer evolves around development of a novel brachytherapy delivery system that can  enable intensity modulated brachytherapy, AI based tumor segmentation and treatment outcome prediction algorithms as well as accurate dose calculation software and dose optimization algorithms. She is also investigating the relative biological effectiveness of different radiation qualities for human rectal cancer cell lines.